Advertisement

Picture EBD Group Biotech Showcase 2025 San Francisco BTS25 650x100px
Document › Details

Verve Capital Partners AG (Verve Ventures). (6/24/22). "Press Release: Verve Ventures Launches Investment Fund to Support Portfolio Companies".

Organisations Organisation Verve Venture Fund I SICAV-RAIF
  Group Verve Capital Partners AG (Verve Ventures, formerly investiere.ch)
  Organisation 2 Memo Therapeutics AG (MTx)
Products Product venture capital
  Product 2 LIFE SCIENCES
Index term Index term Verve Capital Partners–SEVERAL: investment, 202206 1st CHF45m closing of Verve Venture Fund I
Person Person Hobmeier, Mike (Verve Capital Partners 202206)
     


The successful first closing of the CHF 100m fund will accelerate the development of Verve Ventures’ most successful startups.


Verve Ventures has raised its first venture capital fund and closed the first capital call with over 45 Mio. CHF committed capital, from private investors, family offices, and institutional investors. The “Verve Venture Fund I” invests in the best-performing startups among the company’s portfolio of currently more than 140 companies. It will accelerate the development of 15-20 companies with a solid track record at attractive valuations.

Verve Ventures’ investment team has honed its experience over the past 12 years and become one of the most active ones in Europe. The fund will invest in 5-7 companies per year during an investment period of 3 years, followed by a 5-year harvesting period. It will invest across Europe in science and technology-driven companies.

The Verve Venture Fund has already made its first investments, namely in Memo Therapeutics AG (Schlieren, Switzerland), Flyability (Lausanne, Switzerland), and cofenster (Hamburg, Germany). Further investments will be announced soon.

“From fighting diseases like the Coronavirus using antibody discovery to moving drones out of the toybox into real industrial use: the first batch of Verve Venture Fund investments demonstrates the breadth of outstanding companies in Verve’s portfolio. We are looking forward to partnering with our very best portfolio entrepreneurs to grow them into world-leading champions in their field,” said Mike Hobmeier of Verve Ventures.

The second closing of the fund will take place in Q4/2022 and is still open for qualified investors. It is structured as a Luxembourg SICAV-RAIF.


For more information:
Mike Hobmeier
[email protected]
+41 79 403 19 2

   
Record changed: 2023-06-05

Advertisement

Picture EBD Group Biotech Showcase 2025 San Francisco BTS25 650x200px

More documents for Verve Capital Partners AG (Verve Ventures, formerly investiere.ch)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2025 San Francisco BTS25 650x200px




» top